Collegeville, PA, United States of America

Steven David Knight

USPTO Granted Patents = 50 

 

Average Co-Inventor Count = 4.9

ph-index = 11

Forward Citations = 536(Granted Patents)

Forward Citations (Not Self Cited) = 479(Oct 12, 2025)


Inventors with similar research interests:


Location History:

  • King of Prussia, PA (US) (2004 - 2006)
  • West Chester, PA (US) (2003 - 2014)
  • Philadelphia, PA (US) (2009 - 2014)
  • Collegeville, PA (US) (2006 - 2020)

Company Filing History:


Years Active: 2003-2020

Loading Chart...
Loading Chart...
50 patents (USPTO):

Title: Steven David Knight: Pioneering Innovator in Cancer Treatment

Introduction:

In the realm of innovations and patents, individuals like Steven David Knight have made remarkable contributions in revolutionizing cancer treatment. Hailing from Collegeville, PA, Steven David Knight is known for his significant expertise and impressive record of patents. This article explores his latest patents, career highlights, collaborations, and the invaluable impact he has made through his inventive spirit.

Latest Patents:

Steven David Knight's recent patents demonstrate his dedication to addressing the challenging field of cancer treatment. His inventions include compounds and inhibitors of Enhancer of Zeste Homolog 2 (EZH2), which hold promise in therapy for the treatment of various cancers. These novel compounds have the potential to pave the way for more effective and targeted cancer treatments.

Career Highlights:

Throughout his career, Steven David Knight has showcased a strong penchant for innovation. He has accumulated an impressive total of 50 patents, exemplifying his dedication to pushing the boundaries of scientific advancements in cancer research. His work has primarily focused on developing compounds and pharmaceutical compositions that inhibit EZH2, a protein implicated in cancer progression.

Collaborations:

Steven David Knight has had the privilege of collaborating with some prominent individuals and organizations in his journey to develop groundbreaking cancer treatments. Notable collaborations include his work with Cytokinetics, Inc., a leading biopharmaceutical company known for its expertise in muscle biology and the treatment of diseases such as amyotrophic lateral sclerosis (ALS). Additionally, Knight has also collaborated with SmithKline Beecham Corporation, a renowned pharmaceutical company recognized for its contributions to global healthcare.

Co-workers:

Steven David Knight's innovative endeavors have been further supported by the valuable contributions of his colleagues. Notably, he has worked alongside Dashyant Dhanak, an esteemed expert in the field, and Gustave Bergnes, whose insights and expertise have likely played a crucial role in their collaborative endeavors.

Conclusion:

Steven David Knight's pioneering work in cancer treatment has undoubtedly left an indelible mark on the field of medical research. With an impressive array of patents and collaborations under his belt, Knight has demonstrated his commitment to finding innovative solutions to combat cancer. His inventions, particularly those involving EZH2 inhibitors, may hold the key to more effective and precise therapies for cancer patients in the future. As the world continues to battle cancer, exceptional innovators such as Steven David Knight are essential in driving progress towards finding impactful and life-saving treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…